Cargando…

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fuli, Xia, Teng, Li, Zhiqiang, Gao, Xuzhu, Fang, Xinjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505960/
https://www.ncbi.nlm.nih.gov/pubmed/37727216
http://dx.doi.org/10.3389/fonc.2023.1213297
_version_ 1785107018268278784
author Wang, Fuli
Xia, Teng
Li, Zhiqiang
Gao, Xuzhu
Fang, Xinjian
author_facet Wang, Fuli
Xia, Teng
Li, Zhiqiang
Gao, Xuzhu
Fang, Xinjian
author_sort Wang, Fuli
collection PubMed
description Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include chimeric antigen receptor T-cell (CAR-T) therapy, tumor vaccines, immune checkpoint inhibitors, and so forth. Among them, immune checkpoint inhibitors are in the spotlight. Common immune checkpoint inhibitors (ICIs) currently in clinical use include programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1) and cytotoxic T lymphocyte-associated antigen 4(CTLA-4). This article focuses on monotherapy and combination therapy of CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors. In particular, the combination therapy of ICIs includes the combination of ICIs and chemotherapy, the combination therapy of dual ICIs, the combination of ICIs and anti-angiogenic drugs, the combination of ICIs and radiotherapy, and the combination of ICIs inhibitors and tumor vaccines and so forth. This article focuses on the combination therapy of ICIs with chemotherapy, the combination therapy of dual ICIs, and the combination therapy of ICIs with anti-angiogenic drugs. The efficacy and safety of ICIs as single agents in NSCLC have been demonstrated in many trials. However, ICIs plus chemotherapy regimens offer significant advantages in the treatment of NSCLC with little to no dramatic increase in toxicity, while combined dual ICIs significantly reduce the adverse effects (AEs) of chemotherapy. ICIs plus anti-angiogenic agents regimen improves anti-tumor activity and safety and is expected to be the new paradigm for the treatment of advanced NSCLC. Despite some limitations, these agents have achieved better overall survival rates. In this article, we review the current status and progress of research on ICIs in NSCLC in recent years, aiming to better guide the individualized treatment of NSCLC patients.
format Online
Article
Text
id pubmed-10505960
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105059602023-09-19 Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer Wang, Fuli Xia, Teng Li, Zhiqiang Gao, Xuzhu Fang, Xinjian Front Oncol Oncology Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include chimeric antigen receptor T-cell (CAR-T) therapy, tumor vaccines, immune checkpoint inhibitors, and so forth. Among them, immune checkpoint inhibitors are in the spotlight. Common immune checkpoint inhibitors (ICIs) currently in clinical use include programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1) and cytotoxic T lymphocyte-associated antigen 4(CTLA-4). This article focuses on monotherapy and combination therapy of CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors. In particular, the combination therapy of ICIs includes the combination of ICIs and chemotherapy, the combination therapy of dual ICIs, the combination of ICIs and anti-angiogenic drugs, the combination of ICIs and radiotherapy, and the combination of ICIs inhibitors and tumor vaccines and so forth. This article focuses on the combination therapy of ICIs with chemotherapy, the combination therapy of dual ICIs, and the combination therapy of ICIs with anti-angiogenic drugs. The efficacy and safety of ICIs as single agents in NSCLC have been demonstrated in many trials. However, ICIs plus chemotherapy regimens offer significant advantages in the treatment of NSCLC with little to no dramatic increase in toxicity, while combined dual ICIs significantly reduce the adverse effects (AEs) of chemotherapy. ICIs plus anti-angiogenic agents regimen improves anti-tumor activity and safety and is expected to be the new paradigm for the treatment of advanced NSCLC. Despite some limitations, these agents have achieved better overall survival rates. In this article, we review the current status and progress of research on ICIs in NSCLC in recent years, aiming to better guide the individualized treatment of NSCLC patients. Frontiers Media S.A. 2023-09-01 /pmc/articles/PMC10505960/ /pubmed/37727216 http://dx.doi.org/10.3389/fonc.2023.1213297 Text en Copyright © 2023 Wang, Xia, Li, Gao and Fang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Fuli
Xia, Teng
Li, Zhiqiang
Gao, Xuzhu
Fang, Xinjian
Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
title Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
title_full Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
title_fullStr Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
title_full_unstemmed Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
title_short Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
title_sort current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505960/
https://www.ncbi.nlm.nih.gov/pubmed/37727216
http://dx.doi.org/10.3389/fonc.2023.1213297
work_keys_str_mv AT wangfuli currentstatusofclinicaltrialresearchandapplicationofimmunecheckpointinhibitorsfornonsmallcelllungcancer
AT xiateng currentstatusofclinicaltrialresearchandapplicationofimmunecheckpointinhibitorsfornonsmallcelllungcancer
AT lizhiqiang currentstatusofclinicaltrialresearchandapplicationofimmunecheckpointinhibitorsfornonsmallcelllungcancer
AT gaoxuzhu currentstatusofclinicaltrialresearchandapplicationofimmunecheckpointinhibitorsfornonsmallcelllungcancer
AT fangxinjian currentstatusofclinicaltrialresearchandapplicationofimmunecheckpointinhibitorsfornonsmallcelllungcancer